Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-26T18:02:40.753Z Has data issue: false hasContentIssue false
  • English
  • Français

Death Reporting in Breakthrough and Unvaccinated SARS-CoV-2 Infection Cases

Published online by Cambridge University Press:  20 March 2023

Amir Emami Open the ORCID record for Amir Emami [Opens in a new window] ,
Fatemeh Javanmardi Open the ORCID record for Fatemeh Javanmardi [Opens in a new window] ,
Hamid Bakhtiari ,
Tahereh Rezaei ,
Abdolrasoul Hemmati ,
Ali Akbari Open the ORCID record for Ali Akbari [Opens in a new window]  and
Neda Pirbonyeh Open the ORCID record for Neda Pirbonyeh [Opens in a new window]
Amir Emami*
Affiliation:
Microbiology Department, Burn & Wound Healing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Fatemeh Javanmardi
Affiliation:
Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Hamid Bakhtiari
Affiliation:
Vice Chancellor for Health Affairs Center of Disease Control (CDC), Shiraz University of Medical Sciences, Shiraz, Iran
Tahereh Rezaei
Affiliation:
Shiraz University of Medical Sciences, Shiraz, Iran
Abdolrasoul Hemmati
Affiliation:
Department of Pharmacology, Shiraz University of Medical Sciences, Iran
Ali Akbari
Affiliation:
Department of Anesthesiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Neda Pirbonyeh
Affiliation:
Microbiology Department, Burn & Wound Healing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
*
Corresponding author: Amir Emami, Email: emami.microbia@gmail.com.
Get access Rights & Permissions [Opens in a new window]

Abstract

Vaccines are undeniably an important tool for controlling infectious disease outbreaks, and they are the most certain way to end the epidemic risk. This brief report describes the characteristics of coronavirus disease 2019 (COVID-19) deaths among breakthrough and unvaccinated cases hospitalized in Fars province in the south of Iran. This cross-sectional study was performed to compare breakthrough and unvaccinated death cases in Fars, Iran (February 2, to August 19, 2021). Among 444,728 fully vaccinated people, 60,800 breakthrough cases were detected. Thus, 501 died, of which 297 (297/501) cases were hospitalized and compared with the unvaccinated dead group. The median age for breakthrough and unvaccinated cases was estimated 79 and 65 y, respectively. All signs and symptoms of COVID-19 were more frequent in the unvaccinated group. Decreasing O2 saturation (less than 93%) happened more often in the unvaccinated group significantly. Unvaccinated dead patients had significantly shorter hospital stays. These patients received 66.63% Sinopharm, 0.67% Sputnik, 0.67% COVIran Barekat, and 31.99% AstraZeneca vaccines. None of them were health-care staff. Equitable access to safe and effective vaccines is critical to ending the COVID-19 pandemic. As vaccine uptake increases, we observed a decrease in mortality and protection from severe forms of the disease.

Keywords

COVID-19vaccinebreakthrough casesdead
Type
Original Research
Information
Disaster Medicine and Public Health Preparedness , Volume 17 , 2023 , e359
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of Society for Disaster Medicine and Public Health, Inc.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Wolf, J. Bruno, S, Eichberg, M, et al. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. NPJ Vaccines. 2020;5(1):15.CrossRefGoogle ScholarPubMed
Excler, JL, Saville, M, Berkley, S, et al. Vaccine development for emerging infectious diseases. Nat Med. 2021;27(4):591-600.CrossRefGoogle ScholarPubMed
Worldometer, D., COVID-19 coronavirus pandemic. World Health Organization, www. worldometers. info, 2020. https://www.worldometers.info/coronavirus/ Google Scholar
Cleve, MI. What the lightning-fast quest for Covid vaccines means for other diseases. Nature. 2021;589:16-18.CrossRefGoogle Scholar
Kim, JH. SARS-CoV-2 vaccine development, access, and equity. J Exp Med. 2020;217(11):e20201288.CrossRefGoogle ScholarPubMed
van Riel, D, de Wit, E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19(8):810-812.CrossRefGoogle ScholarPubMed
Bergwerk, M, Gonen, T, Lustig, Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474-1484.CrossRefGoogle ScholarPubMed
Butt, AA, Nafady-Hego, H, Chemaitelly, H, et al. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination. Int J Infect Dis. 2021;110:353-358.CrossRefGoogle ScholarPubMed
Sankary, KM, Sippel, JL, Eberhart, AC, et al. Breakthrough cases of COVID-19 in vaccinated United States Veterans with spinal cord injuries and disorders. Spinal Cord. 2021;59(10):1132-1133.CrossRefGoogle ScholarPubMed
Reynolds, MW, Xie, Y, Knuth, KB, et al. COVID-19 vaccination breakthrough infections in a real-world setting: using community reporters to evaluate vaccine effectiveness. Infect Drug Resist. 2022;15:5167-5182.CrossRefGoogle Scholar
CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 vaccine breakthrough infections reported to CDC—United States, January 1–April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(21):792-793.CrossRefGoogle Scholar
Haas, EJ, Angulo, FJ, McLaughlin, JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-1829.CrossRefGoogle ScholarPubMed
Kustin, T, Harel, N, Finkel, U, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021;27(8):1379-1384.CrossRefGoogle ScholarPubMed
Bouton, TC, Lodi, S, Turcinovic, J, et al. COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination strain sequences among healthcare workers at an urban academic medical center: a prospective cohort study. medRxiv. 2021. doi:10.1101/2021.03.30.21254655CrossRefGoogle Scholar
Jacobson, KB, Pinsky, BA, Montez Rath, ME, et al. Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center. Clin Infect Dis. 2022;74(5):821-828.CrossRefGoogle Scholar
Estofolete, CF, Fares, GF, Banho, CA, et al. Predictors of death in COVID-19 vaccine breakthrough infections in Brazil. J Infect. 2022;84(4):e22-e24.CrossRefGoogle ScholarPubMed
Schaffer DeRoo, S, Pudalov, NJ, Fu, LY. Planning for a COVID-19 vaccination program. JAMA. 2020;323(24):2458-2459.CrossRefGoogle ScholarPubMed
Bar-On, YM, Goldberg, Y, Mandel, M, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393-1400.CrossRefGoogle ScholarPubMed
Akbarialiabad, H, Rastegar, A, Bastani, B. How sanctions have impacted Iranian healthcare sector: a brief review. Arch Iran Med. 2021;24(1):58-63.CrossRefGoogle ScholarPubMed
Hacisuleyman, E, Hale, C, Saito, Y, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384(23):2212-2218.CrossRefGoogle ScholarPubMed
Philomina, J B, Jolly, B, John, N, et al. Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India. J Infect. 2021;83(2):237-279.CrossRefGoogle Scholar